StreetInsider.com News Articles

Form 8-K Instil Bio, Inc. For: May 15

Fri, 15 May 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260515/26500124.html

Form 8-K Instil Bio, Inc. For: May 15

Fri, 15 May 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260515/26500124.html

Form 10-Q Instil Bio, Inc. For: Mar 31

Fri, 15 May 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260515/26500138.html

Form 10-Q Instil Bio, Inc. For: Mar 31

Fri, 15 May 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260515/26500138.html

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Fri, 15 May 2026 07:00:00 -0400

DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quarter 2026 financial results and provided a corporate update.

Recent Highlights

Instil is evaluating potential acquisitions and in-licensing that may provide access to promising novel therapeutic candidates
Cash position of approximately $74.7 million as of March 31, 2026 expected to fund current operating plan beyond 2027

“We continue to make progress refining Instil’s strategy and positioning the company for its next phase of growth,” said

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Fri, 15 May 2026 07:00:00 -0400

Recent Highlights

Instil is evaluating potential acquisitions and in-licensing that may provide access to promising novel therapeutic candidates
Cash position of approximately $74.7 million as of March 31, 2026 expected to fund current operating plan beyond 2027

“We continue to make progress refining Instil’s strategy and positioning the company for its next phase of growth,” said

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Fri, 15 May 2026 07:00:00 -0400

Recent Highlights

Instil is evaluating potential acquisitions and in-licensing that may provide access to promising novel therapeutic candidates
Cash position of approximately $74.7 million as of March 31, 2026 expected to fund current operating plan beyond 2027

“We continue to make progress refining Instil’s strategy and positioning the company for its next phase of growth,” said

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Fri, 15 May 2026 07:00:00 -0400

Recent Highlights

Instil is evaluating potential acquisitions and in-licensing that may provide access to promising novel therapeutic candidates
Cash position of approximately $74.7 million as of March 31, 2026 expected to fund current operating plan beyond 2027

“We continue to make progress refining Instil’s strategy and positioning the company for its next phase of growth,” said

Form ARS Instil Bio, Inc. For: Dec 31

Fri, 24 Apr 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260424/26366539.html

Form ARS Instil Bio, Inc. For: Dec 31

Fri, 24 Apr 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260424/26366539.html

Form DEFA14A Instil Bio, Inc.

Fri, 24 Apr 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260424/26366508.html

Form DEFA14A Instil Bio, Inc.

Fri, 24 Apr 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260424/26366508.html

Form DEF 14A Instil Bio, Inc. For: Jun 11

Fri, 24 Apr 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260424/26366476.html

Form DEF 14A Instil Bio, Inc. For: Jun 11

Fri, 24 Apr 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260424/26366476.html

Form 8-K Instil Bio, Inc. For: Apr 01

Fri, 03 Apr 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260403/26270172.html

Form 8-K Instil Bio, Inc. For: Apr 01

Fri, 03 Apr 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260403/26270172.html

Instil Bio Inc. (TIL) Misses Q4 EPS by 97c

Fri, 27 Mar 2026 08:12:59 -0400

Instil Bio Inc. (NASDAQ: TIL) reported Q4 EPS of ($0.97).

For earnings history and earnings-related data on Instil Bio Inc. (TIL) click here.

Form S-8 Instil Bio, Inc.

Fri, 27 Mar 2026 08:07:00 -0400

si-local-file:///var/storage/secattach/20260327/26228340.html

Form S-8 Instil Bio, Inc.

Fri, 27 Mar 2026 08:07:00 -0400

si-local-file:///var/storage/secattach/20260327/26228340.html

Form 10-K Instil Bio, Inc. For: Dec 31

Fri, 27 Mar 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260327/26227978.html

Form 10-K Instil Bio, Inc. For: Dec 31

Fri, 27 Mar 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260327/26227978.html

Form 8-K Instil Bio, Inc. For: Mar 27

Fri, 27 Mar 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260327/26227944.html

Form 8-K Instil Bio, Inc. For: Mar 27

Fri, 27 Mar 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260327/26227944.html

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Fri, 27 Mar 2026 07:00:00 -0400

Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development

Cash position of $76.3 million as of December 31, 2025 expected to fund current operating plan beyond 2027

DALLAS, March 27, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its fourth quarter and full year 2025 financial results and provided a corporate update.

Recent Highlights:

In January 2026, Axion Bio, Inc., a wholly owned subsidiary of Instil, discontinued clinical development of AXN-2510 and entered into

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Fri, 27 Mar 2026 07:00:00 -0400

Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development

Cash position of $76.3 million as of December 31, 2025 expected to fund current operating plan beyond 2027

Recent Highlights:

In January 2026, Axion Bio, Inc., a wholly owned subsidiary of Instil, discontinued clinical development of AXN-2510 and entered into